SENESCENCE AS BIOMARKER OF CANCER-RELATED FATIGUE IN BREAST CANCER PATIENTS RECEIVING ADJUVANT CHEMOTHERAPY
Ente Finanziatore: Fondi 5Xmille istituzionali
Principal Investigator: Dott. Antonuzzo Andrea
Data di inizio:
Data di fine:
Struttura Principale: Oncologia Medica 4 – Cure di Supporto Internistico e Geriatrico
Fatigue is one of the most important side effects of anticancer treatments; in addition to negatively impacting the daily life of patients, it often leads to the re-modulation or suspension of treatments.
Currently, there are no biomarkers useful for both predicting/preventing and treating fatigue. Recent works have linked cellular senescence to the side effects of chemotherapy. In particular, the correlation between the levels of the senescence marker p16 INK4a in circulating T lymphocytes and the development of fatigue following chemotherapy has been demonstrated.
The aim of this project is to evaluate the blood levels of senescence in breast cancer patients who receive an anthracycline-based chemotherapy as an adjuvant (before and after treatment), and to correlate them with the levels of fatigue.
The goal is to understand whether it is possible to predict the onset and extent of fatigue after treatment, and then hypothesize targeted interventions to prevent or mitigate it, and improve patient quality of life.
Principal Investigator Dott. Antonuzzo Andrea
Struttura Principale: Oncologia Medica 4 – Cure di Supporto Internistico e Geriatrico
Area Clinica, Struttura Semplice Dipartimentale
Oncologia Medica 1
Area Clinica, Struttura complessa
Integrated Biology of Rare Tumors
Research Area, Departmental Simple Structure
Biostatistics for Clinical Research
Simple Structure
Last update: 02/09/2025